Does Hormone Therapy Improve Your Cholesterol Profile?
For LDL and total cholesterol, yes. This is a systematic review and meta-analysis of randomized controlled trials, not a single trial: 73 eligible studies of menopause hormone therapy in postmenopausal women. Compared with placebo or no treatment, hormone therapy lowered total cholesterol by a weighted mean difference of 0.43 (95% CI: -0.53 to -0.33), LDL cholesterol by 0.47 (95% CI: -0.55 to -0.40), and lipoprotein(a) by 49.46 (95% CI: -64.27 to -34.64).
Dr. Kumar’s Take
The lipid story here is more specific than the blanket claim that hormone therapy is either good or bad for the heart. The consistent signal is on LDL, total cholesterol, and lipoprotein(a). Triglycerides are where the details of the prescription matter: oral therapy raised triglycerides relative to transdermal, and conventional doses raised them relative to low doses. So when I think about a woman with high triglycerides, the question is not whether to consider hormone therapy but which route and which dose. I also read the estrogen plus progestogen comparison as a caution: adding a progestogen moved TC, LDL-C, and Lp(a) back in the wrong direction relative to estrogen alone. Lipid markers are not cardiovascular outcomes, and this analysis measured markers.
Study Snapshot
This systematic review and meta-analysis searched PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library from inception to December 2020, and included 73 eligible randomized controlled trials of menopause hormone therapy in postmenopausal women. Two reviewers independently extracted data and assessed quality, using the Cochrane risk of bias checklist for methodological quality. The analysis compared hormone therapy against placebo or no treatment, and also compared regimens against each other: oral versus transdermal, low dose versus conventional dose, conventional hormone therapy versus tibolone, and estrogen plus progestogen versus estrogen alone. The review was registered with PROSPERO (CRD42018092924).
Results in Real Numbers
- Versus placebo or no treatment: total cholesterol WMD -0.43 (95% CI: -0.53 to -0.33), LDL-C WMD -0.47 (95% CI: -0.55 to -0.40), lipoprotein(a) WMD -49.46 (95% CI: -64.27 to -34.64)
- Oral versus transdermal: oral therapy produced significantly higher triglycerides, WMD 0.12 (95% CI: 0.04 to 0.21)
- Low dose versus conventional-dose estrogen: low dose favored lower triglycerides, WMD -0.18 (95% CI: -0.32 to -0.03)
- Conventional therapy versus tibolone: conventional therapy lowered LDL-C, WMD -0.35 (95% CI: -0.50 to -0.19), but raised triglycerides, WMD 0.42 (95% CI: 0.18 to 0.65)
- Estrogen plus progestogen versus estrogen alone: higher total cholesterol, WMD 0.15 (95% CI: 0.09 to 0.20), higher LDL-C, WMD 0.12 (95% CI: 0.07 to 0.17), and higher lipoprotein(a), WMD 44.58 (95% CI: 28.09 to 61.06)
Who Benefits Most
The authors single out women with hypertriglyceridemia as the group whose formulation choice matters most: for them, low doses, transdermal delivery, or tibolone would be the safer choice, because oral and conventional-dose regimens pushed triglycerides up. For lipids overall, estrogen alone produced a better profile than estrogen combined with a progestogen, since the combined regimen raised total cholesterol, LDL-C, and lipoprotein(a) relative to estrogen alone.
Safety, Limits, and Caveats
This analysis measured lipid markers, not heart attacks or strokes, so it says what happens to cholesterol numbers and not what happens to cardiovascular events. The triglyceride findings run opposite to the LDL findings for oral and conventional-dose regimens, which is why route and dose are part of the safety conversation rather than a detail. Pooling 73 trials means pooling different formulations, doses, and durations, and the authors themselves describe the benefit of hormone therapy for lipid profiles as having been inconclusive before this analysis.
Practical Takeaways
- Ask about lipids as part of the hormone therapy conversation, since the therapy lowered LDL, total cholesterol, and lipoprotein(a) against placebo or no treatment
- If your triglycerides are high, raise transdermal delivery, a lower dose, or tibolone with your provider, because those were the options the authors called safer for that situation
- Understand that oral therapy raised triglycerides compared with transdermal, so the route is a clinical decision and not just a convenience preference
- Know that adding a progestogen to estrogen shifted total cholesterol, LDL-C, and lipoprotein(a) upward compared with estrogen alone
- Treat improved lipid markers as improved markers, not as a demonstrated reduction in cardiovascular events
- Have your lipid panel checked so any change on therapy is documented rather than assumed
What This Means for Perimenopause and Menopause Care
Dyslipidemia becomes more common after menopause, and this analysis supports the position that menopause hormone therapy plays a positive role in the lipid profile of postmenopausal women. It also refines the conversation. The decision is not simply whether to use hormone therapy, but which formulation, which dose, which route, and whether a progestogen is required, because each of those choices moved the lipid numbers differently in this data. That is the level of detail women deserve when they are weighing symptom relief against long-term health.
Related Studies and Research
- Effects of menopause on temperature regulation
- Estrogen and the Vascular Endothelium: The Unanswered Questions
- Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality
- Recurrent Urinary Tract Infection in Older Outpatient Women
- Episode 27: Perimenopause, Menopause, and HRT - What Every Woman Should Know
FAQs
Will hormone therapy help my high cholesterol?
In this pooled analysis, hormone therapy significantly lowered total cholesterol, LDL cholesterol, and lipoprotein(a) compared with placebo or no treatment. That is a change in your lipid numbers, which is not the same thing as a proven change in your risk of a cardiac event.
What if my triglycerides are already high?
The authors recommend low doses, transdermal delivery, or tibolone as the safer choice for women with hypertriglyceridemia. Oral therapy raised triglycerides compared with transdermal, and conventional doses raised them compared with low doses.
Is oral or transdermal estrogen better for cholesterol?
For triglycerides, transdermal came out ahead: oral therapy led to significantly higher triglycerides than transdermal. Bring your own lipid panel to that decision rather than choosing on convenience alone.
Bottom Line
Across 73 randomized trials, menopause hormone therapy lowered total cholesterol, LDL cholesterol, and lipoprotein(a) in postmenopausal women. The route, the dose, and whether a progestogen is added all change the picture: oral and conventional-dose regimens raised triglycerides, and estrogen plus progestogen blunted the lipid benefit seen with estrogen alone.
